Editorial commentary: dilemma in trial design: do current study designs adequately evaluate effectiveness antibiotic in ABRS?
Marple
Bradley F
BF
Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
D000208:Acute Disease; D017963:Azithromycin / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D015523:Maxillary Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D008863:Microspheres; D015242:Ofloxacin / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012220:Rhinitis / Q000188:drug therapy* / Q000382:microbiology; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D017963:Azithromycin; D015242:Ofloxacin